Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30735778 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 | |
| SCHEMBL9548071 | 0.85 | PTGER4 (0.45) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 | |
| SCHEMBL11893905 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 | |
| SCHEMBL11886837 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 | |
| SCHEMBL31401059 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 | |
| SCHEMBL2782333 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 | |
| SCHEMBL6293695 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 | |
| SCHEMBL942239 | 0.81 | PKM (0.63) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 | |
| SCHEMBL669263 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2L3MBTL1TDP1HSD17B10PKM | |
| SCHEMBL28614221 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1POLBTDP1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20250188033-A1 | INHIBITOR OF REPLICATION PROTEIN A1 OF TRYPANOSOMA BRUCEI AND METHOD OF USE THEREOF | UNIVERSIDAD NACIONAL DE SAN MARTIN (AR) | 2025-06-12 | — | — | US | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-117915903-A | Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| CN-117229257-A | Meta-sulfamoyl benzamide compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2023-12-15 | — | — | CN | disclosed |
| EP-4259118-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2007124546-A1 | INTEGRASE INHIBITORS 3 | AVEXA LIMITED (AU) | 2007-11-08 | — | — | WO | disclosed |
| CN-1803776-A | Substituted benzoyl carbamidine derivative, its preparation method and medical uses | UNIV CHINA PHARMA (CN) | 2006-07-19 | — | — | CN | disclosed |
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1556371-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | Winston Pharmaceuticals LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
| US-6897227-B2 | Prodrugs of proton pump inhibitors | Winston Pharmaceuticals, Inc. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| WO-2004009583-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | GARST MICHAEL E (US) | 2004-01-29 | — | — | WO | disclosed |
| US-3953476-A | DIURETICS | MERCK & CO., INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | SMN1; SMN2 2083/4885L3MBTL1 3178/4885POLB 3596/4885 |
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | SMN1; SMN2 3059/4885L3MBTL1 3697/4885POLB 4417/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | SMN1; SMN2 378/4885L3MBTL1 4696/4885POLB 3712/4885 |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | SMN1; SMN2 2578/4885L3MBTL1 4035/4885POLB 3578/4885 |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | SMN1; SMN2 8/4885L3MBTL1 652/4885POLB 788/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | SMN1; SMN2 2370/4885L3MBTL1 3350/4885POLB 3580/4885 |
| US-20250188033-A1 | INHIBITOR OF REPLICATION PROTEIN A1 OF TRYPANOSOMA BRUCEI AND METHOD OF USE THEREOF | RPA1, RPA3, POLR1A | SMN1; SMN2 3114/4885L3MBTL1 1103/4885POLB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.